Bevacizumab in the treatment of breast cancer

被引：18
|
作者：
Koutras, Angelos K. [1 ]
Fountzilas, George [2 ]
Makatsoris, Thomas [1 ]
Peroukides, Stavros [1 ]
Kalofonos, Haralabos P. [1 ]
机构：
[1] Univ Hosp, Dept Med, Div Oncol, Patras Med Sch, Rion 26504, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Dept Med Oncol, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷 / 01期
关键词：
Bevacizumab; Breast cancer; Treatment; ENDOTHELIAL GROWTH-FACTOR; PACLITAXEL PLUS BEVACIZUMAB; ANTI-VEGF THERAPY; TUMOR-GROWTH; METRONOMIC CHEMOTHERAPY; ANGIOGENIC FACTORS; COLORECTAL-CANCER; EXPRESSION; COMBINATION; RECEPTORS;
D O I：
10.1016/j.ctrv.2009.10.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the Vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free Survival (PFS) of patients with advanced breast cancer. This review presents an update on the clinical studies evaluating the role of bevacizumab in combination with chemotherapy, as well as other agents, both in advanced and early disease. Moreover, although no definitive biomarkers have been identified so far, we provide current data regarding potentially useful predictive factors for treatment with bevacizumab. In addition, we review the Suggested mechanisms that lead to resistance to VEGF targeted therapies and we present recent data with respect to the toxicity of bevacizumab. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：75 / 82
页数：8
相关论文
共 50 条
  • [31] Oncology Breast Cancer: Bevacizumab/Capecitabine Bevacizumab/Paclitaxel
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2016, 76 (12) : 1209 - 1209
  • [32] Panel recommends withdrawing approval for bevacizumab use in breast cancer treatment
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (09) : 1351 - 1351
  • [33] Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
    Link, J. S.
    Waisman, J. R.
    Nguyen, B.
    Jacobs, C. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer
    Earashi, M.
    Matsui, K.
    Maeda, K.
    Fukushima, W.
    Shimada, K.
    Shimizu, T.
    Nozaki, Z.
    Tanada, Y.
    Oyama, K.
    Nagata, T.
    Tsuneda, A.
    Yoshikawa, A.
    Yoshida, T.
    Kiyohara, K.
    Iwata, K.
    Ii, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 32 - 32
  • [35] Use of bevacizumab as a first-line treatment for metastatic breast cancer
    Manso, L.
    Moreno, F.
    Marquez, R.
    Castelo, B.
    Arcediano, A.
    Arroyo, M.
    Ballesteros, A. I.
    Calvo, I.
    Echarri, M. J.
    Enrech, S.
    Gomez, A.
    Gonzalez del Val, R.
    Lopez-Miranda, E.
    Martin-Angulo, M.
    Martinez-Janez, N.
    Olier, C.
    Zamora, P.
    CURRENT ONCOLOGY, 2015, 22 (02) : E51 - E60
  • [36] Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
    Ana Elisa Lohmann
    Stephen Chia
    Current Treatment Options in Oncology, 2012, 13 : 249 - 262
  • [37] Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
    Lohmann, Ana Elisa
    Chia, Stephen
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 249 - 262
  • [38] Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
    Jubb, Adrian M.
    Miller, Kathy D.
    Rugo, Hope S.
    Harris, Adrian L.
    Chen, Dafeng
    Reimann, James D.
    Cobleigh, Melody A.
    Schmidt, Maike
    Langmuir, Virginia K.
    Hillan, Kenneth J.
    Chen, Daniel S.
    Koeppen, Hartmut
    CLINICAL CANCER RESEARCH, 2011, 17 (02) : 372 - 381
  • [39] Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
    Link, John S.
    Waisman, James R.
    Nguyen, Bichlien
    Jacobs, Cheryl I.
    CLINICAL BREAST CANCER, 2007, 7 (10) : 779 - 783
  • [40] Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review
    Pories, Susan E.
    Wulf, Gerburg M.
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 37 - 44
12345